QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.754

Change

+0.03 (+0.26)%

Market Cap

N/A

Volume

1.11K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.23 (+0.45%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.29 (+0.51%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 63.18B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.02 (+0.02%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.01 (+0.00%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.15 (+1.30%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.01 (+0.14%)

USD 43.12B
0ZC:F Zscaler Inc

-1.12 (-0.61%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.15% 66% D+ 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.15% 66% D+ 59% D-
Trailing 12 Months  
Capital Gain 7.24% 44% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.24% 39% F 45% F
Trailing 5 Years  
Capital Gain 56.81% 78% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.81% 78% C+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 12.70% 78% C+ 70% C-
Dividend Return 12.70% 75% C 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.96% 63% D 89% A-
Risk Adjusted Return 115.85% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike